Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ADGRB3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor B3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ADGRB3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor B3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of ADGRB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTPRZ1 Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase zeta Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRZ1 Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase zeta Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTPRZ1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TGFA Biologics Sequence Review Report 2026: Protransforming growth factor alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TGFA Biologics Sequence Review Report 2026: Protransforming growth factor alpha Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TGFA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TFRC Biologics Sequence Review Report 2026: Transferrin receptor protein 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TFRC Biologics Sequence Review Report 2026: Transferrin receptor protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TFRC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CR2 Biologics Sequence Review Report 2026: Complement receptor type 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CR2 Biologics Sequence Review Report 2026: Complement receptor type 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LY86 Biologics Sequence Review Report 2026: Lymphocyte antigen 86 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LY86 Biologics Sequence Review Report 2026: Lymphocyte antigen 86 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LY86 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LIFR Biologics Sequence Review Report 2026: Leukemia inhibitory factor receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LIFR Biologics Sequence Review Report 2026: Leukemia inhibitory factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LIFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CNTFR Biologics Sequence Review Report 2026: Ciliary neurotrophic factor receptor subunit alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CNTFR Biologics Sequence Review Report 2026: Ciliary neurotrophic factor receptor subunit alpha Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CNTFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FOLR2 Biologics Sequence Review Report 2026: Folate receptor beta Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FOLR2 Biologics Sequence Review Report 2026: Folate receptor beta Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FOLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EPOR Biologics Sequence Review Report 2026: Erythropoietin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EPOR Biologics Sequence Review Report 2026: Erythropoietin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EPOR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ESR1 Biologics Sequence Review Report 2026: Estrogen receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ESR1 Biologics Sequence Review Report 2026: Estrogen receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of ESR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EGFR Biologics Sequence Review Report 2026: Epidermal growth factor receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EGFR Biologics Sequence Review Report 2026: Epidermal growth factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →